104 results
8-K
EX-99.1
TNFA
TNF Pharmaceuticals Inc.
26 Jul 24
New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system
4:05pm
related to immune-metabolic dysregulation. A successful and statistically significant small Phase 2 study was completed in 2023, evaluating the safety … safety and efficacy depending on the patient’s need.
TNF Pharmaceuticals retains the registered trademark MYMD-1® for its lead drug program. The Company’s
8-K
EX-99.1
TNFA
TNF Pharmaceuticals Inc.
19 Oct 23
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced
9:00am
inhibitor with the potential to transform the way that TNF-α based diseases are treated. MYMD-1®, with its small molecule design, improved safety profile
8-K
EX-99.1
1024k9bsc
4 Oct 23
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
4:30pm
8-K
EX-99.1
fxi4o4okpzaeqve4
14 Aug 23
Regulation FD Disclosure
8:30am
8-K
EX-99.1
hicgb1zgpwpg 0wyo
3 Aug 23
MyMD Pharmaceuticals Phase 2 Trial Update
4:30pm
8-K
EX-99.1
qfk 2f03qh5tqjp
31 Jul 23
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline
9:00am
8-K
EX-99.1
u52gre8
12 Apr 23
Regulation FD Disclosure
8:45am
8-K
EX-99.1
rs5lu7j 9i44m
8 Dec 22
MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
4:15pm
8-K
EX-99.1
pyr9lso3n3tw
18 Nov 22
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
4:30pm
8-K
EX-99.1
694kd9dm nmmju23
14 Nov 22
MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Data Research
8:32am